White blood cell inactivation after treatment with riboflavin and ultraviolet light

Transfusion

Volumn 50, Issue 11, 2010, Pages 2489-2498

  Marschner, Susanne ^a,b,c,d   Fast, Loren D ^a,b,c,d   Baldwin Iii, William M ^a,b,c,d   Slichter, Sherrill J ^a,b,c,d   Goodrich, Raymond P ^a,b,c,d  

^a CaridianBCT Biotechnologies   (United States)

^b BROWN UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d PUGET SOUND BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; LEUKOCYTE ANTIGEN; RIBOFLAVIN;

ALLOIMMUNIZATION; BLOOD TRANSFUSION; CELL ACTIVATION; CELL FUNCTION; CELL VIABILITY; CLINICAL TRIAL; GAMMA IRRADIATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LEUKOCYTE; REVIEW; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; ULTRAVIOLET RADIATION;

BLOOD PRESERVATION; GRAFT VS HOST DISEASE; HUMANS; LEUKOCYTES; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 78349285465     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02714.x     Document Type: Review

References (47)

1. Schroeder ML,. Transfusion-associated graft-versus-host disease. Br J Haematol 2002; 117: 275 -87.
2. Gould DS, Auchincloss H Jr,. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999; 20: 77 -82.
3. Blajchman MA,. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999; 39: 665 -70.
4. Utter GH, Reed WF, Lee TH, Busch MP,. Transfusion-associated microchimerism. Vox Sang 2007; 93: 188 -95.
5. Blajchman MA,. Immunomodulation and blood transfusion. Am J Ther 2002; 9: 389 -95.
6. Carson JL, Berlin JA,. Will we ever know if leukoreduction of red blood cells should be performed? Can J Anaesth 2004; 51: 407 -10.
7. Pelszynski MM, Moroff G, Luban NL, Taylor BJ, Quinones RR,. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994; 83: 1683 -9.
8. Mintz PD, Wehrli G,. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant 2009; 44: 205 -11.
9. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE, Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C, McClelland DB, Norfolk DR, Soldan K, Taylor C, Revill J, Williamson LM, Cohen H,. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20: 273 -82.
10. Serious Hazards of Transfusion Steering Committee. Serious hazards of transfusion: annual report 2008. [cited 2010 Apr 30]. Manchester (UK): SHOT Office; 2009. Available from
11. Taswell C,. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981; 126: 1614 -9.
12. Fast LD, DiLeone G, Li J, Goodrich R,. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642 -8.
13. Van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, De Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, Van Bloois L, Rijkers G, Martens AC, Ebeling SB,. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/-gammac-/-double-mutant mice. Blood 2003; 102: 2522 -31.
14. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich R,. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/-double knockout mice. Transfusion 2006; 46: 1553 -60.
15. The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. In press 2009.
16. Custer B, Agapova M, Havlir Martinez R,. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion. In press 2010.
17. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM,. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174 -82.
18. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R,. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106 -14.
19. Jackman RP, Heitman JW, Marschner S, Goodrich RP, Norris PJ,. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 2009; 49: 2686 -99.
20. Bessos H, Murphy WG, Robertson A, Vickers M, Seghatchian MJ, Tandy NP, Cutts M, Pamphilon DH,. Quality of platelet concentrates irradiated with UVB light: effect of UV dose and dose rate on glycocalicin release and correlation with other markers of the platelet storage lesion. Transfus Med 1993; 3: 115 -21.
21. Johnson RB, Napychank PA, Murphy S, Snyder EL,. In vitro changes in platelet function and metabolism following increasing doses of ultraviolet-B irradiation. Transfusion 1993; 33: 249 -55.
22. Sherman L, Menitove J, Kagen LR, Davisson W, Lin A, Aster RH, Buchholz DH,. Ultraviolet-B irradiation of platelets: a preliminary trial of efficacy. Transfusion 1992; 32: 402 -7.
23. Snyder EL, Beardsley BR, Smith RR, Horne W, Johnson R, Wooten T, Napychank PA, Male P, Buchholz DH,. Storage of platelet concentrates after high-dose ultraviolet B irradiation. Transfusion 1991; 31: 491 -6.
24. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP,. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335 -41.
25. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns Adu P,. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279 -85.
26. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861 -9.
27. Coppage M, Baker M, Fialkow L, Meehan D, Gettings K, Chen L, Massey HT, Blumberg N,. Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products. Hum Immunol 2009; 70: 413 -6.
28. Muylle L, Peetermans ME,. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 66: 14 -7.
29. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, Constantini LA, Patterson B, Roberts RS, Thorpe KE, Levine MN,. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42: 556 -66.
30. Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL,. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004; 44: 16 -24.
31. Yazer MH, Podlosky L, Clarke G, Nahirniak SM,. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004; 44: 10 -5.
32. Heddle NM,. Universal leukoreduction and acute transfusion reactions: putting the puzzle together. Transfusion 2004; 44: 1 -4.
33. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME,. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33: 195 -9.
34. Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R,. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006; 90: 85 -91.
35. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R,. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131 -7.
36. Goodrich RP, Edrich RA, Li J, Seghatchian J,. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5 -17.
37. Goodrich RP, Gilmour D, Hovenga N, Keil SD,. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205 -16.
38. Rentas F, Harman R, Gomez C, Salata J, Childs J, Silva T, Lippert L, Montgomery J, Richards A, Chan C, Jiang J, Reddy H, Li J, Goodrich R,. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007; 47: 240 -7.
39. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP,. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877 -85.
40. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, Ravanat JL, Cadet J, Goodrich RP,. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15 -21.
41. Setlow RB, Setlow JK,. Effects of radiation on polynucleotides. Annu Rev Biophys Bioeng 1972; 1: 293 -346.
42. Przepiorka D, Leparc GF, Stovall MA, Werch J, Lichtiger B,. Use of irradiated blood components: practice parameter. Am J Clin Pathol 1996; 106: 6 -11.
43. Goodrich RP, Doane S, Reddy H,. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20 -30.
44. Goodrich RP, Doane S, Reddy HL,. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20 -30.
45. Hornsey VS, Drummond O, Morrison A, McMillan L, MacGregor IR, Prowse CV,. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009; 49: 2167 -72.
46. Larrea L, Calabuig M, Roldan V, Rivera J, Tsai HM, Vicente V, Roig R,. The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 2009; 41: 199 -204.
47. Smith J, Rock G,. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010; 50: 926 -31.